Media headlines about Cerecor (NASDAQ:CERC) have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cerecor earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the company an impact score of 48.8710820633164 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of brokerages recently weighed in on CERC. TheStreet raised Cerecor from an “e+” rating to a “c-” rating in a research report on Wednesday, November 8th. ValuEngine raised Cerecor from a “strong sell” rating to a “sell” rating in a research report on Tuesday, November 7th.
Cerecor (CERC) traded up $0.01 during trading on Tuesday, reaching $1.01. The company’s stock had a trading volume of 151,500 shares, compared to its average volume of 501,992. Cerecor has a 52 week low of $0.34 and a 52 week high of $5.60. The stock has a market capitalization of $26.05, a PE ratio of 100.00 and a beta of 2.13.
Cerecor (NASDAQ:CERC) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.15. Cerecor had a return on equity of 212.90% and a net margin of 51.71%. The company had revenue of $0.16 million during the quarter. equities analysts expect that Cerecor will post 0.83 EPS for the current fiscal year.
In other Cerecor news, major shareholder Armistice Capital Master Fund purchased 219,792 shares of the firm’s stock in a transaction on Monday, August 21st. The stock was bought at an average cost of $0.60 per share, for a total transaction of $131,875.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders acquired 1,638,693 shares of company stock valued at $1,053,475. 10.70% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Cerecor (CERC) Stock Price” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2017/11/14/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-cerecor-cerc-stock-price.html.
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.